Application of PET/CT to the molecularly-targeted therapy for thyroid cancer patients

Application of PET/CT to the molecularly-targeted therapy for thyroid cancer patients - PET for TC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024766

Enrollment

Registered

2016-12-01

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cancer

Interventions

PET/CT examination performed before and 1 month after the molecularly-targeted therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult thyroid cancer patients who are scheduled to receive molecularly-targeted therapy at Tokyo Women's Medical University

Exclusion criteria

Exclusion criteria: 1. Pregnant women and women suspected of being pregnant 2. Patients with an incurable malignancy other than thyroid cancer 3. Patients present hyperglycemia (>200 mg/dL) 4. Patients present a poor image quality of PET/CT 5. Patients judged as inadequate trial subjects

Design outcomes

Primary

Measure	Time frame
FDG or MET uptake at before and 1 month after the initiation of molecularly-targeted therapy	—

Countries

Japan

Contacts

Public ContactKoichiro Abe

Tokyo Women's Medical University Diagnostic Imaging and Nuclear Medicine

abe.koichiro@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026